S1PR1: A Drug Target / Disease Biomarker (G1901)

Target Name: S1PR1

NCBI ID: G1901

S1PR1

S1PR1: A Drug Target / Disease Biomarker

S1PR1, also known as S1PR1G, is a protein that is expressed in many tissues throughout the body. It is a member of the S1P family of transmembrane proteins, which are known for their involvement in various signaling pathways. One of the functions of S1PR1 is to regulate the expression of genes in the cell, and it has been shown to play a role in a number of biological processes, including cell signaling, inflammation, and stress response.

Recent studies have suggested that S1PR1 may be a drug target or biomarker for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because S1PR1 has been shown to be involved in the regulation of cellular processes that are often disrupted in these conditions, and drugs that can modulate S1PR1 activity may have therapeutic benefits.

One of the potential benefits of targeting S1PR1 is its potential to inhibit the development and progression of cancer. S1PR1 has been shown to play a role in the regulation of cell proliferation and has been shown to promote the growth of cancer cells. Therefore, drugs that can inhibit S1PR1 activity may have anti-cancer properties.

Another potential benefit of targeting S1PR1 is its potential to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. S1PR1 has been shown to play a role in the regulation of cellular processes that are involved in the development and progression of these conditions, and therefore may be a useful target for therapies that aim to treat these conditions.

In addition to its potential therapeutic benefits, S1PR1 is also a potential biomarker for a number of diseases. Because S1PR1 is involved in the regulation of cellular processes that are often disrupted in these conditions, it may be a useful indicator of the severity of these conditions. For example, levels of S1PR1 have been shown to be elevated in the brains of individuals with Alzheimer's disease, and therefore may be a useful biomarker for this condition.

Targeting S1PR1 is still in the early stages of research, and it is likely that more studies will be needed to fully understand its potential therapeutic and biomarker properties. However, its potential as a drug target and biomarker is an exciting area of research, and further studies are likely to shed light on its role in the regulation of cellular processes and its potential as a therapeutic agent.

Protein Name: Sphingosine-1-phosphate Receptor 1

Functions: G-protein coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. Plays an important role in cell migration, probably via its role in the reorganization of the actin cytoskeleton and the formation of lamellipodia in response to stimuli that increase the activity of the sphingosine kinase SPHK1. Required for normal chemotaxis toward sphingosine 1-phosphate. Required for normal embryonic heart development and normal cardiac morphogenesis. Plays an important role in the regulation of sprouting angiogenesis and vascular maturation. Inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. Required for normal egress of mature T-cells from the thymus into the blood stream and into peripheral lymphoid organs. Plays a role in the migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis (By similarity). Plays a role in responses to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine by pulmonary endothelial cells and in the protection against ventilator-induced lung injury

The "S1PR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S1PR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets